i
Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic
-
Feb 2008
Source: Emerg Infect Dis. 14(2):267-274.
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:A decision analytical model was developed to investigate the cost-effectiveness of stockpiling antiviral (AV) drugs for a potential influenza pandemic in the United Kingdom and the possible role of near-patient testing in conserving AV drug stocks. Under base-case assumptions (including a fixed stockpile that was smaller than the clinical attack rate), the treat-only option (treating all symptomatic patients with AV drugs) would be considered cost-effective ( pound1,900- pound13,700 per quality-adjusted life year [QALY] gained, depending on the fatality scenario), compared with no intervention (nonintervention but management of cases as they arise). The test-treat option (testing all symptomatic patients but treating those with positive tests results only) would result in moderate gains in QALYs over the treat-only option but at relatively large additional costs. Stockpiling sufficient AV drugs (but not near-patient tests) to treat all patients with clinical cases would be cost-effective, provided AV drugs are effective at preventing deaths from pandemic influenza.
-
Subject:
-
Source:
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
Supporting Files
-
gif jpeg gif jpeg gif pdf txt txt gif jpeg gif jpeg gif jpeg gif jpeg
More +